Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Files for Approval of Exforge OD Tablets
March 3, 2014
- Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
- Mizuho Projects 5% Upswing for FY2014 Operating Profit of 9 Major Japan Pharmas
February 28, 2014
- Nipro Opens Sales Subsidiary in Sweden
February 28, 2014
- Fujifilm Sets Up Chinese Subsidiary for Regenerative Medicine Business, Eyeing Provision of Epidermis Culturing Services by 2015
February 28, 2014
- All DPP-4 Inhibitors to Undergo Major Price Reductions Due to Market Expansion of Januvia/Glactiv; Re-pricing Could Affect SGLT-2 Inhibitors as Well
February 28, 2014
- 72 Drug Makers Provided 483 Billion Yen in Funding to Medical and Research Institutions in FY2012
February 27, 2014
- Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
- Shionogi Announces Reorganization to Boost R&D Capabilities
February 26, 2014
- Ranbaxy’s Toansa, Dewas Plants Voluntarily Suspend API Shipments Worldwide
February 26, 2014
- Takeda to Realign Japan Sales Team
February 25, 2014
- Ajinomoto Aims to Increase Operating Profit Rate to 10% in Pharmaceuticals Segment in FY2016 Under New Midterm Plan
February 24, 2014
- Multinational PIII Study of Revlimid for Follicular Lymphoma Starts in Japan: Celgene
February 24, 2014
- Sanofi to Begin Standalone Generic Operation in Japan
February 24, 2014
- Over 90% of Drug Makers Increasing Sales Rep Calls to Wholesalers Due to Imposed Restrictions
February 24, 2014
- ASKA Launches Leuplin Generic
February 21, 2014
- Diabetes Drug Sales Up 10% in 2013 Japan Market, Spurred by DPP-4 Inhibitors: IMS
February 21, 2014
- Plavix Tops Japan Ethical Drug Ranking, Sales Leap 14%: IMS
February 21, 2014
- US FDA Approves Droxidopa: DSP
February 20, 2014
- MTPC, Daiichi Sankyo Aim to Boost Sales of Struggling Tenelia
February 20, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…